Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents

Not Applicable

Recruiting

• Conditions: Blood Pressure

• Registration Number: NCT05874479
• Lead Sponsor: NYU Langone Health

Brief Summary

Fine particulate matter \<2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor portable air cleaners (PACs) are a novel approach to reduce exposure to PM2.5 and potentially lower blood pressure. The current study is being conducted to provide evidence that PACs reduce PM2.5 exposure and lower systolic blood pressure (SBP) in key patient populations.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-05-12
• Study First Submitted QC: 2023-05-12
• Study First Posted: 2023-05-25
• Study Start: 2023-12-20
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-21
• Last Update Posted: 2024-11-22
• Primary Completion: 2027-09
• Study Completion: 2028-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 440

Inclusion Criteria

• self-reported nonsmokers living in a nonsmoking household.
• adults living with hypertension (HTN) from NYC public housing.

Exclusion Criteria

• History of major known arrhythmias (e.g. atrial flutter or fibrillation, ventricular tachycardia).
• Screening systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg (i.e. severe hypertension by the 2017 ACC/AHA BP guideline).
• A change in drug regimen in the prior 2 weeks or a planned change in drug regimen during the first 30 days for those taking antihypertensive medication.
• Current smoking or living with an active smoker who smokes indoors
• Planned travel out of NYC for ≥2 weeks in next 6 months
• Incarcerated
• Pregnant
• Unable/unwilling to consent
• Established cardiovascular disease
• End-stage renal disease (chronic kidney disease stage IV or on dialysis)
• Barrier to technology use (e.g., visual or hearing impairment)
• Lung disease requiring oxygen
• Cancer receiving treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 30 Days	Up to Day 30	Participants measure HBP every day between 6-9 am.

Secondary Outcome Measures

Name	Time	Method
Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 90 Days	Up to Day 90	Participants measure HBP every day between 6-9 am.
Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 180 Days	Up to Day 180	Participants measure HBP every day between 6-9 am.

Trial Locations

Locations (1)

NYU Langone Health; 🇺🇸 New York, New York, United States